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Immunological functions of mast cells remain poorly
understood. Studies in Kit mutant mice suggest
key roles for mast cells in certain antibody- and
T cell-mediated autoimmune diseases. However,
Kit mutations affect multiple cell types of both
immune and nonimmune origin. Here, we show that
targeted insertion of Cre-recombinase into the mast
cell carboxypeptidase A3 locus deleted mast cells
in connective and mucosal tissues by a genotoxic
Trp53-dependent mechanism. Cre-mediated mast
cell eradication (Cre-Master) mice had, with the
exception of a lack of mast cells and reduced baso-
phils, a normal immune system. Cre-Master mice
were refractory to IgE-mediated anaphylaxis, and
this defect was rescued by mast cell reconstitution.
This mast cell-deficient strain was fully susceptible
to antibody-induced autoimmune arthritis and to
experimental autoimmune encephalomyelitis. Differ-
ences comparing Kit mutant mast cell deficiency
models to selectively mast cell-deficient mice call
for a systematic re-evaluation of immunological func-
tions of mast cells beyond allergy.
INTRODUCTION
Whereas the central role of IgE, high-affinity Fc receptors (FcR)
for IgE (FcεRI), and mast cells in IgE-mediated allergic diseases
is evident, other pathological or protective immunological func-
tions of mast cells remain enigmatic. Insight into in vivo mast
cell functions relies primarily on animals lacking mast cells.832 Immunity 35, 832–844, November 23, 2011 ª2011 Elsevier Inc.Mutations in the gene encoding the receptor tyrosine kinase
Kit are referred to as white-spotted (W) Kit alleles and cause
mast cell deficiency. Hypomorphic KitW/Wv (Kitamura et al.,
1978) and, more recently, KitW-sh/W-sh (Berrozpe et al., 1999;
Grimbaldeston et al., 2005) mutants have served as standard
models to study mast cell functions. However, Kit signaling is
not only important for mast cell development but also affects
many other lineages, including hematopoietic stem and progen-
itor cells, red blood cells, neutrophils, intestinal pacemaker cells,
melanocytes, and germ cells. Also, Kit is involved in the regula-
tion of pain and metabolic responses (reviewed in Besmer
et al., 1993; Broudy, 1997; Di Santo and Rodewald, 1998;
Fleischman, 1993; Galli et al., 1994). Because pleiotropic Kit
functions have hampered an unequivocal assignment of a given
phenotype specifically to the lack of mast cells, strategies have
been developed to selectively reconstitute Kit mutants with
bone marrow-derived cultured mast cells (BMMC) (Nakano
et al., 1985). In this approach, nonreconstituted Kit mutants are
compared to BMMC-reconstituted Kit mutants in any given
assay (Tsai et al., 2005). By and large, this system is the founda-
tion of the current concept of mast cells as key immunological
elements involved in an increasing list of physiological and path-
ological functions. These encompass not only roles for mast
cells in positive or negative regulation of innate and adaptive
immune responses (reviewed in de Vries and Noelle, 2010; Galli
et al., 2008) and in defense against bacterial infections (reviewed
in Abraham and St John, 2010) and toxins (Metz et al., 2006;
Schneider et al., 2007) but also invoke mast cell contributions
to autoimmunity (Benoist and Mathis, 2002; Sayed et al.,
2008), obesity and diabetes (Liu et al., 2009), arteriosclerosis
(Kovanen, 2009), and cancer (Tlsty and Coussens, 2006). Given
the underlying Kit deficiency, it remains ambiguous to what
extent the absence of mast cells is, in fact, responsible for the
observed phenotypes. It is also noteworthy that in Kit mutants
mast cell deficiency cannot readily be combined with key
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(MHC) haplotypes, genetic backgrounds, or informative immu-
nological mutations. The mast cell deficiency is largely limited
in KitW/Wv mice to the WB 3 C57BL/6 genetic background (for
origin of MHC in this strain see Waskow et al., 2009) and for
KitW-sh/W-sh mice predominantly, but not completely (Lu et al.,
2006), to the C57BL/6 genetic background (Grimbaldeston
et al., 2005). Taken together, mouse strains wild-type for Kit,
but selectively deficient for mast cells, and on defined genetic
backgrounds would be advantageous.
We show here that expression of Cre recombinase from the
mast cell carboxypeptidase A (Cpa3) locus (Feyerabend et al.,
2009) selectively abrogated mast cells in vivo. Themast cell defi-
ciency in ‘‘Cre-mediated mast cell eradication’’ (Cre-Master)
mice was Kit independent and constitutive. We subjected Cre-
Master mice to passive autoantibody-driven arthritis and active
immunization-driven experimental autoimmune encephalomy-
elitis (EAE), i.e., models of autoimmunity in which major propa-
thogenic roles for mast cells had been reported in Kit mutants
(Lee et al., 2002; Secor et al., 2000; reviewed in Sayed et al.,
2008). We found no evidence for an involvement of mast cells
in these two models of autoimmune diseases, thus providing
examples in which analyses of mast cells in Kit mutant mice
may not reflect mast cell functions in a normal immune system.
RESULTS
Ablation of Connective Tissue Mast Cells by Expression
ofCreRecombinase from theCarboxypeptidaseA Locus
The Cpa3 gene, which encodes the mast cell protease carboxy-
peptidase A (Cpa3), is considered a mast cell-specific gene
(Reynolds et al., 1989) that is expressed from the earliest mast
cell progenitors on (Rodewald et al., 1996). To drive Cre ex-
pression in the mast cell lineage, we generated mice in which
improved Cre recombinase (iCre), mutated according to
mammalian codon usage (Shimshek et al., 2002), was inserted
via homologous recombination into the Cpa3 locus, which
yielded the Cpa3Cre allele (Figure S1 available online; Feyer-
abend et al., 2009). Rather than finding Cre expression in mast
cells, we noted a complete absence of mast cells in the perito-
neal cavity from heterozygous Cpa3Cre/+ gene-targeted mice
(Figures 1A and 1B). Lack of mast cells was evident by flow
cytometric comparison of peritoneal lavage cells from Cpa3+/+
and Cpa3Cre/+ mice for the mast cell phenotype Kit+FcεRI+
(Figures 1A and 1B; quantified in 1E). To test whether mast cells
were morphologically present but lacked expression of Kit and
FcεRI, cytospins from peritoneal lavage cells were examined
for mast cell-typical metachromatic May-Gru¨nwald-Giemsa
staining (Figures 1A and 1B). Again, mast cells were undetect-
able in Cpa3Cre/+ mice. We extended these findings to the skin,
another prominent anatomical location for connective tissue
mast cells (CTMC). Ears from Cpa3+/+ and Cpa3Cre/+ mice
were stained by toluidine blue and by chloroacetate esterase,
and dye-reactive cells were found in skin from wild-type but
not Cpa3Cre/+ mice (Figures 1C and 1D).
Next, we comprehensively searched for a mast cell gene
expression signature in normally mast cell-bearing tissues. Total
mRNAs from peritoneal lavage cells (Figure 1F) and skin (Fig-
ure 1G) of Cpa3+/+, Cpa3Cre/+, and KitW/Wv mice were subjectedIto whole-genome gene expression analyses. Consistent with
their specific expression in CTMC, the protease genes Cma2,
Cpa3, Mcpt4, Mcpt5, and Mcpt6 were strongly represented
among peritoneal lavage- and skin-derived mRNAs from wild-
type mice. Of note, none of these mast cell-specific transcripts
was detectable in Cpa3Cre/+ or in KitW/Wv mRNAs (Figures 1F
and 1G). As expected from connective tissues, mucosal mast
cell- or basophil-associated proteases (Mcpt1, Mcpt2, Mcpt8,
Mcpt9) were not expressed in peritoneal cells and skin in any
of the strains. In further support of the lack of mast cell products,
expression of Fcer1a and Kit was undetectable in the peritoneal
cavity of Cpa3Cre/+ and KitW/Wv mice. In the skin, Kit-expressing
cells include mast cells and melanocytes (Aoki et al., 2009;
Peters et al., 2002). Consistent with the lack of mast cells but
not melanocytes, Kit expression was reduced in Cpa3Cre/+
skin. The source of this remaining Kit expression was nonhema-
topoietic because Kit+CD45+ cells were undetectable by flow
cytometry in the skin of Cpa3Cre/+ mice. Kit+ cells, which were
detected by immunhistology in the skin of Cpa3Cre/+ mice,
lacked mast cell gene expression and were exclusively localized
in close vicinity to hair follicles (not shown). This is consistent with
the characteristics of melanocyte lineage cells. In KitW/Wv skin,
lack of melanocytes, evident by absence of melanocyte-specific
gene (Si and Dct) expression, and mast cells abrogated Kit
expression. Gata2, a transcription factor important for mast
cell development, and histidin decarboxylase (Hdc), which is
expressed in mast cells and monocytes, were similarly reduced
in Cpa3Cre/+ and KitW/Wv compared to wild-type mice. Collec-
tively, the complete loss of mast cell products in tissues that
are normally rich in mast cells supports the conclusion that
Cpa3Cre/+ mice are fully mast cell deficient. A direct comparison
of mast cell signatures in Cpa3Cre/+ and KitW/Wv mice demon-
strates that the extent of mast cell deficiency was indistinguish-
able in both strains. Analysis for gene expression of Fc receptors,
interleukins (Il) Il4, Il6, Il9, Il10, as well as Tnf and Ifng in the peri-
toneal cavity and in skin (Figures 1F and 1G), and of chemokines,
chemokine receptors, and adhesion molecules in spleens (not
shown) revealed no effect of Cre-mediated mast cell ablation
on these parameters.
Skin mast cell numbers can be markedly increased by chronic
inflammation. After repeated exposure of skin over 6 weeks to
phorbol-12-myristate-13-acetate (PMA), mast cell numbers
increased 3- to 4-fold in wild-type mice. The relative increase
in mast cell numbers was even higher (10- to 100-fold) in the
skin of normally mast cell-deficient KitW/Wv mice (Figure 1H;
Gordon and Galli, 1990; Waskow et al., 2007). Hence, inflamma-
tory signals can partially overcome the block in mast cell devel-
opment in KitW/Wv mice. In contrast, the skin of Cpa3Cre/+ mice
remained free of mast cells when challenged by chronic skin
inflammation (Figure 1I). Taken together,Cpa3Cre/+ mice showed
a complete and constitutive absence of mast cells in peritoneal
cavity and in skin, which was accompanied by the loss of
a mast cell gene expression signature. Even under conditions
of chronic skin inflammation, no mast cells were induced in
Cpa3Cre/+ mice.
Cpa3Cre/+ Mice Lack Mucosal Mast Cells in the Intestine
At mucosal sites, mast cells are very rare unless induced by
infection or inflammation. To generate intestinal mastocytosis,mmunity 35, 832–844, November 23, 2011 ª2011 Elsevier Inc. 833
Figure 1. Cpa3Cre/+ Mice Lack Mast Cells in
the Peritoneal Cavity and the Skin
(A and B) Peritoneal lavage cells from Cpa3+/+ (A,
left) and Cpa3Cre/+ (B, left) mice were analyzed by
flow cytometry without prior forward and side
scatter gating for the presence of Kit+FcεRI+ mast
cells (gated regions in A and B). Expression of
FcεRI was revealed by anti-IgE staining. Numbers
show percentages of mast cells in total peritoneal
lavage cells. Cytospins from peritoneal lavage
cells from Cpa3+/+ (A, right) and Cpa3Cre/+ (B,
right) mice were analyzed by May-Gru¨nwald-
Giemsa staining for metachromatic mast cells.
The insert (A, right) shows a 33 magnification of
the neighboring mast cell (arrow). Details on the
generation of the Cpa3Cre allele are given in Fig-
ure S1.
(C and D) Ear skin sections from Cpa3+/+ (C) and
Cpa3Cre/+ (D) mice were analyzed by toluidine
blue for metachromatic mast cells (left) and by
chloroacetate esterase for purple-stained mast
cells (right).
Scale bars represent 50 mm.
(E) Quantification of absolute numbers of mast
cells in the peritoneal cavity of Cpa3+/+ (closed
circle) (54,000 ± 1,500 [one standard deviation];
n = 12 mice) and Cpa3Cre/+ (open square) (0.0 ±
0.0; n = 12) mice. Numbers were determined by
flow cytometry. Each symbol represents an indi-
vidual mouse.
(F and G) Mast cell gene expression signature in
peritoneal lavage cells (F) and in ears (G). Total
mRNAs from peritoneal lavage cells were ana-
lyzed by global gene expression arrays. The
genes listed on the right were compared between
Cpa3+/+, Cpa3Cre/+, and KitW/Wv mice (each n = 3).
(G) Total mRNAs from ears were analyzed as in (F)
and compared between Cpa3+/+, Cpa3Cre/+, and
KitW/Wvmice (each n = 2). The heat maps in (F) and
(G) are globally normalized for all genes shown in
each panel, and the color code (bottom) shows
the corresponding differences in gene expression.
(H and I) Mast cell numbers after repeated expo-
sure of skin over 6 weeks to phorbol-12-myr-
istate-13-acetate (PMA). In (H), untreated (closed
circle) (540 ± 247 mast cells per cm ear skin, n = 6)
and PMA-treated (open circle) (1,734 ± 454, n = 6)
Kit+/+ mice were compared to untreated (closed
triangle) (1.3 ± 0.8, n = 6) and PMA-treated (open triangle) (179 ± 136, n = 6) KitW/Wv mice. In (I), untreated (closed circle) (404 ± 95, n = 5) and PMA-treated
(open circle) (2,008 ± 363, n = 5) Cpa3+/+ mice were compared to untreated (closed square) (0.2 ± 0.3, n = 5) and PMA-treated (open square) (10 ± 12.8, n = 5)
Cpa3Cre/+ mice. Numbers were determined histologically by toluidine blue staining, and each symbol represents an individual mouse.
Immunity
Role of Mast Cells in Autoimmunity Revisitedwe infected mice with the prototypic T helper 2 (Th2) cell-
inducing helminth Nippostrongylus brasiliensis (Nb). Mast cells
resident in the lamina propria and epithelium of the small intes-
tine in helminth-infected mice selectively express mast cell
protease 1 (Mcpt1), a mucosal mast cell (MMC)-specific marker
(Friend et al., 1996). In a first set of experiments, small intestines
were taken 10 days after the infection, and histological sections
were analyzed by toluidine blue staining. Although numerous
MMCs were induced in the mucosa of Cpa3+/+ mice (Figure 2A),
MMCs remained undetectable in Cpa3Cre/+ mice (Figure 2B). In
a second set of experiments, we evaluated the mucosal mast
cell response based on local and systemic Mcpt1 expression.
In noninfected mice, Mcpt1 mRNA was found at very low834 Immunity 35, 832–844, November 23, 2011 ª2011 Elsevier Inc.amounts and Mcpt1 protein was undetectable. At 14 days after
the infection, abundant quantities of Mcpt1 mRNA and Mcpt1
protein were induced only in Cpa3+/+ mice. In Cpa3Cre/+ mice,
Mcpt1 mRNA expression did not increase compared to nonin-
fected mice, and Mcpt1 protein remained undetectable (Figures
2C and 2D). In further characterization ofMcpt1mRNA-express-
ing cells in Cpa3Cre/+ mice, we quantified by flow cytometry the
percentage and the absolute number of mast cell progenitors
(MCPs) (Arinobu et al., 2005). The results show that MCPs
were barely detectable in Cpa3Cre/+ (absolute number of cells =
1.68 ± 0.49 3 102; n = 4) compared to Cpa3+/+ (11.7 ± 6.18 3
102; n = 4) mice (Figure S2). RT-PCR analysis of sorted cells
for Mcpt1 mRNA identified the few MCPs as a likely source of
Figure 3. Lack of Anaphylaxis in Cpa3Cre/+ Mice and Rescue of the
Defect by Mast Cell Transplantation
(A–C) Cpa3Cre/+ and control mice were analyzed by systemic passive
anaphylaxis. Data on local (cutaneous) anaphylaxis are shown in Figure S3.
(A) Systolic blood pressure in anesthetized Cpa3+/+ (closed circle) and
Cpa3Cre/+ (open square) mice was recorded in the carotid artery after sensi-
tization by intravenous injection of anti-DNP IgE and challenge on the next day
by intravenous injection with DNP-human serum albumin. Cpa3+/+ and
Cpa3Cre/+ mice were analyzed pair-wise on the same day. Data shown are
representative for one out of two experiments with one mouse per genotype in
each experiment.
(B) Rectal temperatures of Cpa3+/+ (closed circle) and Cpa3Cre/+ (open square)
were recorded in 10min intervals and are expressed as temperature difference
(D) compared to starting temperature. Mice were sensitized as in (A) and
challenged on the subsequent day by intravenous injection with DNP-Oval-
bumin. Shown are the mean ± SEM for five mice per genotype.
(C) Mast cell transplantation rescues anaphylaxis in Cpa3Cre/+ mice. BMMC-
transplanted Cpa3Cre/+ mice were challenged as described in (B), and the
temperature drop was recorded (closed diamond) (n = 5). Negative control
Cpa3Cre/+ mice also received mast cells, but IgE was omitted prior to antigen
challenge (open diamond) (n = 5). As positive controls, Cpa3+/+ mice were
included and treated as described in (C) (closed circle) (n = 3). In all mice, rectal
temperatures were recorded in 10 min intervals and are expressed as
temperature difference (D) compared to starting temperature. Shown are the
mean ± SEM.
Figure 2. Cpa3Cre/+ Mice Lack Mucosal Tissue Mast Cells
(A and B) Cpa3+/+ and Cpa3Cre/+ mice were infected with the helminth
Nippostrongylus brasiliensis. The small intestine was taken 10 days post-
infection, and sections from the jejunum from Cpa3+/+ (n = 3) (A) and Cpa3Cre/+
(n = 3) (B) mice were analyzed for mucosal mast cells by toluidine blue staining.
Arrows point at mast cells in the mucosa in Cpa3+/+ mice that were absent
in Cpa3Cre/+ mice.
(C and D) Intestinal mRNA (C) and serum (D) samples, taken 14 days post-
infection from Cpa3+/+ (n = 5) and Cpa3Cre/+ (n = 5) mice and from noninfected
mice (n = 2 for each genotype), were analyzed for expression of Mcpt1. In (C),
Mcpt1 mRNA expression was analyzed by RT-PCR on mice of the indicated
genotype with and without infection. For relative comparison, cDNAs were
diluted in 10-fold steps, and templates were normalized for Actb mRNA
expression (see also Figure S2). In (D), serum concentrations of Mcpt1 were
determined by ELISA, and results are shown for uninfected (closed circle) and
infected (open circle) Cpa3+/+ mice and for uninfected (closed square) and
infected (open square) Cpa3Cre/+ mice. Each symbol represents an individual
mouse.
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MCPs express Mcpt1 mRNA and Mcpt1 marker expression
was not induced in response to Nb infection in Cpa3Cre/+ mice,
it is very unlikely that MCPs participate in this inflammatory
response. Altogether, Cpa3Cre/+ mice were unable to generate
a mucosal mast cell response to Nb infection.
Cpa3Cre/+ Mice Are Refractory to IgE-Driven
Anaphylactic Responses
To functionally test for the absence of mast cells, we subjected
mice to IgE-mediated local and systemic anaphylacticIresponses (Figure 3; Figure S3). Mice were injected intradermally
into the ear or intravenously with anti-dinitrophenyl (DNP) IgE
monoclonal antibody, followed on the next day by systemic chal-
lenge with hapten (DNP)-carrier antigens with (local) or without
(systemic) Evans blue as an extravasation tracer. For bettermmunity 35, 832–844, November 23, 2011 ª2011 Elsevier Inc. 835
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Cpa3+/+ and Cpa3Cre/+ mice on the white BALB/c background.
In IgE- but not in PBS control-injected ears, Evans blue extrava-
sated within 5 min into the tissue. InCpa3Cre/+ mice, IgE-injected
ears remained white (Figure S3).
Systemic IgE-mediated anaphylactic responses were
measured by changes in systolic blood pressure and in body
temperature. Systolic blood pressure was read in anesthesia
after catheterization of the carotid artery (Albuszies et al., 2005)
in mice loaded with IgE on the previous day. After intravenous
antigen challenge, the mean blood pressure rose from
95 mm Hg to 170 mm Hg within 2 min, followed by a sudden
andmassive drop to60mmHg, fromwhere it slowly recovered
(Figure 3A). This blood pressure response coincided with
a marked increase in heart rate from 400 to >550 beats per
min, which also returned to the baseline over time. This hemody-
namic response pattern is typical for a nonlethal anaphylactic
shock. In Cpa3Cre/+ mice, blood pressure (Figure 3A) and heart
rate remained unaffected by the antigen challenge. When body
temperature was read as a measure for systemic anaphylaxis
under nonlethal conditions, Cpa3+/+mice showed a severe tran-
sient drop in body temperature whereas Cpa3Cre/+ mice did not
respond (Figure 3B). To examine whether mast cells would
restore anaphylactic responsiveness, Cpa3Cre/+ mice were
transplanted with cultured mast cells. Mast cell-reconstituted
Cpa3Cre/+ mice mounted a normal anaphylactic temperature
drop that was comparable to that of wild-type mice (Figure 3C).
Collectively, Cpa3Cre/+ mice were resistant to IgE-mediated
anaphylaxis, and this deficiency could be rescued by mast cell
transplantation.
Genotoxicity and Trp53 Dependency of Cpa3Cre-Driven
Mast Cell Ablation
Cre-mediated cell ablation was cell intrinsic to the hematopoietic
system becausewild-type bonemarrow stem cells reconstituted
donormast cells in irradiatedCpa3Cre/+ recipients, andCpa3Cre/+
bonemarrow stem cells were unable to reconstitute mast cells in
KitW/Wv mice (Figure S4). Loss of mast cells in Cpa3Cre/+ gene-
targeted mice was not due to the heterozygous disruption of
the Cpa3 gene because even homozygous Cpa3/ gene-defi-
cient mice have normal numbers of mast cells (Feyerabend
et al., 2005). Southern blotting showed that the targeting
construct had inserted correctly into the Cpa3 locus (Figure S1),
whereas no other gene has been disrupted in this strain.
Cpa3 is very strongly expressed in mast cells (discussed
further below). In cell lines and in mice, strong or prolonged
expression of Cre has been reported to exert genotoxicity via
cutting of ‘‘endogenous loxP-like sites’’ in the mouse genome
(Naiche and Papaioannou, 2007; Schmidt-Supprian and Rajew-
sky, 2007), and Cre-induced genotoxicity can result in chromo-
somal abnormalities (Higashi et al., 2009). To search for such
signs of Cre toxicity, we derived bone marrow mast cells
(BMMCs) from Cpa3Cre/+ mice. Despite the fact that Cpa3Cre/+
bone marrow was extremely inefficient in generating mast cells
in vitro compared to wild-type bone marrow (Figure S4), the
resulting cells provided sufficient material for further character-
ization. In contrast to wild-type BMMCs that had a normal karyo-
type, chromosome spreads from Cpa3Cre/+ BMMCs included
a fusion chromosome (Figure S4). To identify the chromosome836 Immunity 35, 832–844, November 23, 2011 ª2011 Elsevier Inc.that contributed to this pseudotrisomy and to identify further
gains or losses, we subjected genomic DNA from Cpa3Cre/+
BMMCs to array-based comparative genomic hybridization
(aCGH). This higher-resolution technique revealed a large dele-
tion on chromosome 7 and two small deletions on chromosomes
7 and 11 in this preparation. The major part of chromosome 16
was duplicated, consistent with the large fusion chromosome
visualized by the chromosome spreads (Figure S4). Such
genomic lesions are compatible with a genotoxic mechanism
of mast cell ablation.
We hypothesized that p53 (Trp53)-dependent DNA repair and
apoptosis pathways (reviewed in Vousden and Lane, 2007)might
be activated in Cpa3Cre/+ mast cells in response to Cre-induced
DNA double-strand breaks and that repeated DNA lesions might
drive mast cells into apoptosis. To test this possibility, we
crossed Cpa3Cre/+ mice onto a Trp53/ background. As
expected, mast cells were present in control (Cpa3+/+Trp53+/+
and Cpa3+/+Trp53/) but not in Cpa3Cre/+Trp53+/+ mice. Inter-
estingly, peritoneal mast cells were partially rescued inCpa3Cre/+
on a Trp53/ background (Figure 4A). Consistent with Cre-
induced genomic lesions, rescued peritoneal mast cells, but
not wild-type mast cells, showed multinucleated or fragmented
nuclei (Figure 4B). Loss of Trp53 in Cpa3Cre/+ mice also rescued
mast cells in the skin (Figure 4C). The fact that this rescue was
only partial in terms of cells per mouse and numbers of mice
with mast cells (Figure 4D) suggests that rescued mast cells
were highly unstable evenwhen the Trp53 pathwaywas blocked.
Collectively, the data imply that strong expression of Cre
recombinase causes DNA breaks in mast cells, evident by
genomic imbalances, and that mast cell ablation occurs by
a Trp53-dependent mechanism.
Hematological and Immunological Parameters
and Th2 Cell-Dependent Antibody Response
in the Absence of Mast Cells
To establish key immunological and hematological parameters,
we determined in the peripheral blood of Cpa3+/+ and Cpa3Cre/+
mice (C57BL/6 background) counts of total white blood cells, red
blood cells, platelets, hematocrit, and percentages of lympho-
cytes, monocytes, and neutrophils. None of these parameters
differed between normal andmast cell-deficientmice (Figure 5A).
Spleens were analyzed for immature and mature B cell popula-
tions, for naive, activated, and memory CD4+ and CD8+ T cells,
and for neutrophils, macrophages, and dendritic cell populations
(Figure S5). None of these populations was affected by the
absence of mast cells. The only cell type other than mast cells
that was affected in Cpa3Cre/+ mice were splenic basophils
(1.62 ± 0.61 3 105 in Cpa3+/+ mice versus 0.63 ± 0.21 3 105 in
Cpa3Cre/+ mice; n = 12 for each genotype). Basophils were
also reduced in KitW/Wv spleens (0.18 ± 0.05 3 105 basophils
per spleen; n = 7) (Figure S5), which is in agreement with the re-
ported reduction of basophils in KitW/Wv blood (Mancardi et al.,
2011). Finally, no differences were observed for IgM, IgG1,
IgG2a, IgG2b, IgG3, IgA, and IgE serum titers comparing nonim-
munized Cpa3+/+ and Cpa3Cre/+ mice (Figure 5B), which implies
that IgE titers are regulated independently of IgE adsorption by
FcεRI-bearing mast cells.
To elicit a Th cell-dependent antibody response predominated
by IL-4-mediated IgG1 class switch, mice were immunized with
Figure 4. Mechanism of Cre Recombinase-Medi-
ated Ablation of Mast Cells
(A) Peritoneal lavage cells from mice of the indicated
genotypes were analyzed by flow cytometry for the pres-
ence of Kit+FcεRI+ mast cells. Two examples are provided
for Cpa3Cre/+Trp53/ mice. Numbers in the gates show
percentages of mast cells in total peritoneal lavage cells.
(B) May-Gru¨nwald-Giemsa-stained cytospins of perito-
neal lavage cells of the indicated genotypes, showing
multinucleated or fragmented nuclei in rescued mast cells
from Cpa3Cre/+Trp53/ mice. Further information on the
mechanism of mast cell ablation is given in Figure S4.
(C) Histological analysis of ear skin mast cells of the indi-
cated genotypes by chloroacetate esterase staining.
(D) Quantification of mast cells in the ears of Cpa3Cre/+
Trp53/mice. Mast cells were counted on chloroacetate
esterase-stained sections as in (C). Each symbol repre-
sents an individual mouse.
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immunization, anti-NP IgG1 serum titers were indistinguishable
comparing Cpa3+/+ and Cpa3Cre/+ mice (Figure 5C). Hence,
mast cell-deficient mice can mount a normal T cell-dependent
antibody response to hapten-carrier including class switch (Fig-
ure 5C) and hypermutation (not shown).
Taken together, with the exception of reduced basophils, all
tested hematological and immunological parameters did not
differ between Cpa3+/+ and Cpa3Cre/+ mice. Likewise, the lack
of mast cells in Cpa3Cre/+ mice had no impact on a Th2 cell-
dependent antibody response.
Impact of Mast Cell Deficiency and Kit Deficiency
on Susceptibility to Antibody-Induced Arthritis
in the K/BxN Model
The concept that mast cells contribute to autoimmunity has
gained considerable attention (reviewed in Benoist and Mathis,
2002; Sayed et al., 2008). This was propelled by the inability to
induce the K/BxN serum transfer arthritis in mast cell-deficient
KitW/Wv mice and in mast cell-deficient Kit ligand (Kitl)-mutated
KitlSl/Sld mice (Lee et al., 2002). In the K/BxN autoimmune arthritis
model (Kouskoff et al., 1996), K/BxN mice spontaneously pro-
duce IgG antibodies that react with the ubiquitous cytoplasmic
enzyme glucose-6-phosphate isomerase (GPI). IntraperitonealImmunity 35, 832–(i.p.) injection of K/BxN serum passively trans-
fers the arthritis to naive recipient mice with
rapid onset within days and severe progression
(Korganow et al., 1999). Immune complex
depositions in the joints initiate and promote
inflammation and joint destruction (reviewed in
Benoist and Mathis, 2002).
To analyze the susceptibility of Kit-proficient
mice lacking mast cells to serum transfer
arthritis, we challengedCpa3Cre/+ mice and their
wild-type Cpa3+/+ controls (both C57BL/6), as
well as KitW/Wv mice (WB 3 C57BL/6 F1) by
i.p. injections with K/BxN mouse serum (Fig-
ure 6). Cpa3+/+ and Cpa3Cre/+ mice were litter-
mates kept together in common cages, and
the scoring was done on genotype-blindanimals. This routine procedure, which avoids experimental
bias, has not been possible before because WB 3 C57BL/6 F1
KitW/Wv mice are white whereas control WB 3 C57BL/6 F1
Kit+/+mice are black. KitW/Wv mice were bred from heterozygous
parents in the same mouse room as the Cpa3+/+ and Cpa3Cre/+
mice.
Each day after the first injection of the K/BxN serum, hind limb
ankle thickness and the clinical score were recorded. In the first
experiment, we compared Cpa3+/+, Cpa3Cre/+, and KitW/Wv mice
(Figure 6A). Wild-typemice showed the reported rapid onset and
severe progression of disease. Both ankle joint swelling and
clinical score peaked around day 12 and improved thereafter
but did not fully resolve. KitW/Wv mice were protected from the
disease, except for very mild and transient symptoms (Lee
et al., 2002). In contrast to KitW/Wv mice, Cpa3Cre/+ mice were
clearly susceptible. Hence, KitW/Wv mice were protected
whereas both Cpa3+/+ and Cpa3Cre/+ mice developed severe
arthritis. This finding was confirmed in a second experiment
comparing Cpa3+/+ and Cpa3Cre/+ mice (Figure 6B). Data in
Figures 6A and 6B were subjected to a two-way ANOVA con-
sidering time and genotypes to evaluate differences in re-
sponse curves. No significant differences between Cpa3+/+
and Cpa3Cre/+ genotypes were observed (p values > 0.05 for
clinical scores and for ankle thickness in Figures 6A and 6B).844, November 23, 2011 ª2011 Elsevier Inc. 837
Figure 5. Hematological and Immunolog-
ical Parameters, Including a Th2 Cell-De-
pendent Antibody Response in the Absence
of Mast Cells
(A) Peripheral blood from Cpa3+/+ (closed circle)
and Cpa3Cre/+ (open square) mice was analyzed
for total cell numbers of white blood cells (WBC),
red blood cells (RBC), platelets (PLT), hematocrit
(HCT), and percentages of lymphocytes (Lymph),
monocytes (Mono), and neutrophils (Neutro).
Detailed data on hematopoetic populations are
shown in Figure S5.
(B) Serum immunoglobulin concentrations of IgM,
IgG1, IgG2a, IgG2b, IgG3, IgA, and IgE were
determined for nonimmunized Cpa3+/+ (closed
circle) andCpa3Cre/+ (open square) mice. In (A) and
(B), each symbol represents an individual mouse.
None of the values differed significantly between
Cpa3+/+ and Cpa3Cre/+ mice (all p values > 0.05 for
Cpa3+/+ versus Cpa3Cre/+ mice).
(C) Anti-NP IgG1 titers were measured in pre-
immune (closed circle) and immunized (open
circle) Cpa3+/+ (n = 7) and in preimmune (closed
square) and immunized (open square) Cpa3Cre/+
(n = 7) mice 14 days after immunization with
NP-chicken gamma globulin. Serum dilutions are
plotted versus optical density (OD) readings. Each
line represents an individual mouse.
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uations of ankle joints from K/BxN serum-injected Cpa3+/+mice,
which showed massive leukocyte infiltrations, erosion of the
cartilage, and destruction of the functional joint. These patholog-
ical alterations were also present in ankle joints of Cpa3Cre/+ but
not of KitW/Wv or PBS-injected Cpa3+/+ mice (Figure 6C).
As a measure of disease progression and severity, we next
compared arthritis-associated changes in gene expression. In
this third independent experiment, ankle joints were collected
from naive mice and from mice 3 and 7 days after the first injec-
tion of K/BxN serum. Global gene expression analysis revealed
several distinct patterns: (1) genes that are upregulated toward
day 7, (2) genes that are upregulated beginning on day 3 and
continuing through day 7, (3) genes that are, regardless of the
time point, present in Cpa3+/+ but absent in Cpa3Cre/+ mice,
and (4) genes that are downregulated toward day 7. Patterns
1, 2, and 4 are reminiscent of an earlier report (Jacobs et al.,
2010) and were comparable between Cpa3+/+ and Cpa3Cre/+
mice (Figure 6D). This is further support for the comparable clin-
ical course and histopathological data obtained in these two
strains (Figures 6A–6C). Pattern 3 showed that the mast cell
products Cma2, Cpa3, Mcpt4, and Mcpt5 were not present in838 Immunity 35, 832–844, November 23, 2011 ª2011 Elsevier Inc.the joints of Cpa3Cre/+ mice before or
during the joint inflammation. In further
search for mast cell products, we also
analyzed joints by RT-PCR for expression
of Mcpt4, Mcpt5, Mcpt6, and Fcer1a
(Figure 6E). As a control for induction
of arthritis, we included inflammatory
markers Saa3 and Mmp3, which are up-
regulated in arthritic joints in this model
(Jacobs et al., 2010). All of these mastcell genes were expressed in joints of Cpa3+/+ mice and did
not increase with inflammation. None of the mast cell products
examined in the mRNA array or in the RT-PCR were found in
naive or inflamed joints of Cpa3Cre/+ mice (Figures 6D and 6E).
In brief, K/BxN antibody arthritis did not induce mast cell prod-
ucts in Cpa3Cre/+ joints at any time point analyzed, and mast
cell products, although present in wild-type mice, were not upre-
gulated in the course of the disease.
Collectively, disease progression and severity were evaluated
based on joint thickness, clinical scores, histopathology, and
arthritis-associated changes in gene expression. The results
showed that mast cell-deficient Cpa3Cre/+ mice and wild-type
Cpa3+/+ controls were comparably susceptible in the K/BxN
autoimmune arthritis model, whereas KitW/Wv mice were largely
protected. The full susceptibility of Cpa3Cre/+ mice makes the
idea of a crucial role for mast cells in this immune complexmodel
of arthritis unlikely.
Cpa3Cre/+ and KitW/Wv Mice Are Susceptible
to Experimental Autoimmune Encephalomyelitis
It has been reported thatmast cells are important in experimental
autoimmune encephalomyelitis (EAE), which serves as a model
Figure 6. Antibody-Induced Arthritis Inde-
pendent of Mast Cells but Dependent on Kit
(A and B) Kinetics and severity of K/BxN serum
transfer arthritis in Cpa3+/+ (closed black circle),
Cpa3Cre/+ (closed red square), and KitW/Wv (closed
blue triangle) mice. In experiment 1 (A), Cpa3+/+,
Cpa3Cre/+, and KitW/Wv mice (n = 5 for each
genotype) were compared, and in experiment 2
(B), Cpa3+/+ and Cpa3Cre/+ mice (n = 5 for each
genotype) were analyzed side-by-side. Clinical
scoring (Clinical index) was done as described in
Experimental Procedures, and the data are plotted
as mean daily clinical score ± SEM for all animals
per group. Ankle thickening is expressed as
increase in thickness (D) compared to the baseline
ankle thickness of each paw and is shown as the
mean ± SEM of both hind limbs. No significant
differences between Cpa3+/+ and Cpa3Cre/+
genotypes were observed for clinical scores (A,
p = 0.11; B, p = 0.95) and for ankle thickness (A, p =
0.38; B, p = 0.81).
(C) Histopathological analysis of ankle joints.
10 days after injection of K/BxN serum (Cpa3+/+,
Cpa3Cre/+, and KitW/Wv) or saline (Cpa3+/+ PBS),
joints were stained by hematoxylin and eosin
(H&E). The affected Cpa3+/+ joint shows very
severe destructive rheumatoid-like osteoarthritis
with tendovaginitis and adjacent granuloma
formation. It is further characterized by active,
granulocytic inflammation giving rise to granulo-
cytic exudates into tendon sheaths and appear-
ance of metaplastic ossifocation within the
inflammatory pannus. Similarly, the Cpa3Cre/+ joint
suffers from severe proliferative and granuloma-
tous rheumatoid-like arthitis and tendovaginitis
with osteoarthrosis. In contrast, the joints from
K/BxN serum-injected KitW/Wv mice and the non-
injected Cpa3+/+ control present as normal joints
without any pathology.
(D) Changes in gene expression in response to
K/BxN serum arthritis. Global mRNA expression
was analyzed in ankle joints from naive mice
(day 0) and from mice 3 and 7 days after the first
injection of K/BxN serum. For each genotype and
time point, a total of five joints from 3–4 individual
mice were analyzed. Four distinct patterns of
changes in gene expression are indicated on the
left (1–4) (see Results). Pattern 3 shows lack of
mast cell products in Cpa3Cre/+ mice at all time
points.
(E) RT-PCR analysis on 4-fold dilutions of the
cDNAs (joints as described in D) for expression of
mast cell products Mcpt4, Mcpt5, Mcpt6, and
Fcer1a, of inflammatory markers Saa3 andMmp3,
and of Actb as positive control.
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distribution correlate with the development of MS or EAE (re-
viewed in Sayed et al., 2008), and KitW/Wv and KitW-sh/W-sh mice
were reported to be more resistant than Kit+/+ mice to myelin
oligodendrocyte glycoprotein (MOG)35–55 (termed MOG)
peptide-induced EAE (Secor et al., 2000; Stelekati et al., 2009).
Cpa3+/+, Cpa3Cre/+, andKitW/Wvmice were subjected toMOG-
induced EAE (Figures 7 and S6; Mendel et al., 1995). We moni-
tored onset of disease, incidence of diseased mice, numbers
of moribund mice, and the maximal score (see ExperimentalIProcedures for the scoring system) over the observation period.
Cpa3+/+ and Cpa3Cre/+ mice were mixed littermates that were
scored without prior knowledge of their Cpa3 genotype.
We compared Cpa3+/+, Cpa3Cre/+, and KitW/Wv mice in three
independent EAE experiments (Figures 7 and S6). Analysis of
Cpa3+/+ (n = 19), Cpa3Cre/+ (n = 19), and KitW/Wv (n = 11) mice
revealed comparable days of onset of disease (mean 10.6 ±
1.1 [one standard deviation; SD] for Cpa3+/+; 11.0 ± 1.6 for
Cpa3Cre/+; 11.1 ± 0.9 for KitW/Wv) (Figures 7A–7D and S6). The
incidence was 100% in all three strains and the maximal scoremmunity 35, 832–844, November 23, 2011 ª2011 Elsevier Inc. 839
Figure 7. Experimental Autoimmune En-
cephalomyelitis Independent of Mast Cells
and Independent of Kit
(A–D) Kinetics and severity of MOG-induced EAE
in Cpa3+/+ (A), Cpa3Cre/+ (B), and KitW/Wv (C) mice.
Overlay (D) shows direct comparison of Cpa3+/+
(black circle), Cpa3Cre/+ (red circle), and KitW/Wv
(blue circle) mice. Shown are the mean ± SEM of
the clinical score with n = 5 for each genotype.
Based on a two-way ANOVA considering time and
genotypes, no significant differences were found
in (D) (p = 0.92 for Cpa3+/+ versus Cpa3Cre/+, p =
0.69 for Cpa3+/+ versus KitW/Wv, and p = 0.74 for
Cpa3Cre/+ versus KitW/Wv) (see also Figure S6).
(E) Total mononuclear cells in the central nervous
system (CNS). Naive (n = 4) and MOG-immunized
(n = 12) mice were compared in a total of four
independent experiments.
(F–H) Numbers of lymphocytes (F), activated
(CD44+CD62L) CD4+ (G), and CD8+ (H) T cells in
the CNS of naive andMOG-immunizedmice of the
indicated genotypes.
(I) Numbers of Gr1+ granulocytes in the CNS of
naive and MOG-immunized mice of the indicated
genotypes.
(J and K) In vitro proliferative response of splenic
CD4+ (J) andCD8+ (K) T cells fromnaive andMOG-
immunized mice of the indicated genotypes.
(L) Splenic CD4+ T cells as described in (J) were
stimulated overnight with MOG peptide and the
percentages of IFN-g+CD4+ T cells were deter-
minedby flowcytometry after intracellular cytokine
staining.
Analyses in (E)–(L) were done 11 days after immu-
nization. Data in (E) summarize four independent
experiments. In (F)–(L), naive (n = 2) and MOG-
immunized (n = 6) mice were compared in two
independent experiments. In (E)–(L), the indicated
genotypes of all MOG-immunized mice were
statistically compared and none were found
significantly different (all p values > 0.05).
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for KitW/Wv mice. Finally, numbers of moribund mice were 4/19
(21%) for Cpa3+/+, 3/19 (16%) for Cpa3Cre/+, and 5/11 (46%)
for KitW/Wv mice (Figure S6). Based on a two-way ANOVA
considering time and genotypes, no significant differences
were found between any of the strains (Figures 7D, S6A, and
S6B: p values > 0.05 for all comparisons of Cpa3+/+ versus
Cpa3Cre/+, Cpa3+/+ versus KitW/Wv, and Cpa3Cre/+ versus KitW/Wv
mice). Hence, all three strains were indistinguishable for the
onset of disease, the mean maximal score, and the incidence.
In further search for genotype-related differences, we
analyzed the extent of leukocyte infiltration into the central
nervous system (CNS) and the associated effector T cell
response in MOG-immunized mice (Figures 7E–7L). These anal-
yses were done on day 11 postimmunization, i.e., at the begin-
ning of the onset of clinical signs of disease. Consistent with840 Immunity 35, 832–844, November 23, 2011 ª2011 Elsevier Inc.neurological symptoms, absolute num-
bers of leukocytes retrieved from the
CNS strongly increased in all three strains
compared to nonimmunized mice (Fig-ure 7E). Cpa3+/+, Cpa3Cre/+, and KitW/Wv mice showed a compa-
rable increase in CD45hi lymphocytes (Figure 7F), which included
both CD4+ and CD8+ T cells with an activated-memory pheno-
type (CD44+CD62L) (Figures 7G and 7H). All three strains
showed strong influx of Gr1+ neutrophils to the CNS at day 11
postimmunization (Figure 7I), whereas the relative fraction of
F4/80+ cells (probably mostly microglia) declined relative to
neutrophils (not shown). MOG immunization led to an in vivo
expansion of MOG-reactive T cells as shown by proliferation of
splenic CD4+ and CD8+ T cells (Figures 7J and 7K) and IFN-g
production byCD4+ T cells upon restimulationwithMOGpeptide
in vitro (Figure 7L).
In summary, these experiments demonstrated that normal
Cpa3+/+ and mast cell-deficient Cpa3Cre/+ mice were indistin-
guishably susceptible to the development of MOG-induced
EAE. Unexpectedly, KitW/Wv mice were equally vulnerable
Immunity
Role of Mast Cells in Autoimmunity Revisitedcompared to Cpa3+/+ or Cpa3Cre/+ mice, suggesting that neither
mast cell deficiency nor Kit deficiency affect the clinical or immu-
nological manifestation of MOG-induced EAE.
DISCUSSION
Since the discovery that mast cell development depends on Kit
(Kitamura et al., 1978), Kit mutants have been used to examine
in vivo mast cell functions. KitW/Wv mice not only lack mast cells
but suffer from additional defects, notably anemia, neutropenia,
and lack of subsets of intraepithelial lymphocytes. In addition,
they show impairments in lymphocyte development, gut motility,
and pain sensation. KitW-sh/W-sh mice display a milder spectrum
of abnormalities and, given their fertility and their C57BL/6 back-
ground, seem a better model than KitW/Wv mice (Grimbaldeston
et al., 2005). However, the genetic inversion in KitW-sh/W-sh mice
is associated with further hematopoietic abnormalities, including
splenomegaly with expanded myeloid and megakaryocyte
populations, neutrophilia (in contrast to the neutropenia of
KitW/Wv mice), and thrombocytosis (Nigrovic et al., 2008; Zhou
et al., 2007).
To distinguish Kit deficiency from mast cell deficiency, mast
cell-reconstitution of Kit mutants became an experimental
cornerstone for studies of in vivo mast cell functions (Tsai
et al., 2005). A definitive separation of Kit deficiency from mast
cell deficiency may be aided by Kit mutation-independent mast
cell-deficient mice. Here, we have presented a mouse mutant
that satisfies these criteria. Mast cell deficiency was demon-
strated by several independent approaches, i.e., flow cytometry,
histology, mRNA array analyses, and after challenges with intes-
tinal parasites, during acute arthritis, and in chronic PMA-
induced dermatitis. By none of these criteria did Cre-Master
mice harbor mast cells or their products. Functionally, Cre-
Master mice did not respond when challenged by anaphylaxis,
and this defect was rescued by reintroduction of mast cells.
In the light of the widespread use of Cre, it was surprising to
find full mast cell ablation in Cpa3Cre/+ mice. What could be the
mechanism of mast cell ablation? Based on a Cpa3humanCD4
gene-targeted reporter mouse, in which Cpa3 expression can
be visualized by cell surface expression of human CD4 (unpub-
lished), the Cpa3 locus is weakly expressed in several hemato-
poietic progenitors, including splenic basophil and mast cell
progenitors (BMCPs) (Arinobu et al., 2005), and in splenic baso-
phils. Consistent with weak expression of the Cpa3 locus,
splenic BMCPs were present in normal numbers in Cpa3Cre/+
mice. In contrast, Cpa3 expression in mast cells is very strong,
i.e., 14-fold higher than in BMCPs. This progressive increase
of Cpa3 expression with development was paralleled by a
concomitant loss of cells (not shown). The partial reduction in
basophils is probably caused by a similar mechanism because
Cpa3 is also expressed in this cell type. In Cpa3Cre/+ mice, baso-
phils in the spleen were reduced to40%. This reduction should
be considered when immunological functions are assessed in
this strain. Markedly reduced numbers of basophils in peripheral
blood (Mancardi et al., 2011) and spleen (this paper) in KitW/Wv
mice suggest that a combined effect on these developmentally
related lineages may not be unique for Cpa3Cre/+ mice.
Cpa3Cre/+ BMMCs carried genomic deletions and a pseudo-
trisomy that is supportive of a genotoxic mechanism of mastIcell ablation. The mast cell rescue showed that this mechanism
is, at least partly, Trp53 dependent. The lethal effect of Cpa3Cre
expression on mast cells is reminiscent of a selective ablation of
basophils in Mcpt8-Cre BAC transgenic mice (Ohnmacht et al.,
2010), suggesting that both mast cells and basophils are sensi-
tive to Cre overexpression. It remains to be determined whether
these two lineages are more sensitive to genotoxicity of Cre
than other cell types. Finally, global analysis of the expression
of chemokines, cytokines, Fc receptors, and adhesion mole-
cules revealed that the mechanism of mast cell ablation in Cre-
Master mice does not cause any apparent signs of inflammation
or ongoing immune responses.
Recently, two other mouse lines have been generated with the
aim of expressing Cre in mast cells. In contrast to Cpa3Cre/+
mice, in which Cre was inserted via gene targeting, Mcpt5-Cre
(Scholten et al., 2008) and alpha-chymase promoter-Cre
(Chm:Cre) (Mu¨sch et al., 2008) strains are transgenic lines. All
three strains have distinct patterns of Cre expression. Whereas
Cpa3Cre is expressed in all mast cell subtypes, including the
progenitor, Mcpt5-Cre mice display expression in connective
tissues (peritoneal cavity and skin) while Chm:Cre mice show
a mucosal expression pattern (lung and colon but not peritoneal
cavity). A further difference is the constitutive mast cell deletion
by the Cpa3Cre allele, which does not occur in Mcpt5-Cre and
Chm:Cre mice. Hence, Cpa3Cre/+ mice represent a constitutive
mast cell deficiency model, whereas Mcpt5-Cre and Chm:Cre
allow deletion of floxed genes in distinct mast cell populations.
Mast cells havewidely been considered enigmatic cells whose
physiological functions and medical importance beyond the
undesired allergy might still await discovery (Galli, 1993; Kaliner,
1979). Among the recently suggested functions for mast cells
were protective roles (‘‘sentinels of pathogens’’) not only against
parasites but also against bacteria and viruses (reviewed in
Abraham and St John, 2010). In addition, several authors have
recently emphasized immunomodulatory mechanisms in which
both innate and adaptive immune responses are guided early
on by mast cells and their products (Galli et al., 2005, 2008;
Abraham and St John, 2010; Frossi et al., 2010; Dietrich et al.,
2010). In this context belong reports that mast cells are key
cellular elements in autoimmune diseases (reviewed in Benoist
and Mathis, 2002; Sayed et al., 2008; de Vries and Noelle,
2010). As a new entry point for a systematic analysis of the
possible roles of mast cells in autoimmunity, we have focused
our experiments by using Cre-Master mice on two prominent
models of autoimmune diseases, autoantibody-driven arthritis
and EAE. In the case of the K/BxN arthritis, we confirmed an
earlier finding that KitW/Wv mice are overall resistant while wild-
type mice are susceptible (Lee et al., 2002). However, our result
that Kit+/+ mice lacking mast cells (Cpa3Cre/+) are fully suscep-
tible to the disease makes roles for mast cells in this particular
autoimmune pathology unlikely. The discrepancy between
susceptible Kit+/+ mice lacking mast cells (Cpa3Cre/+) and resis-
tant KitW/Wv mice suggests an important role for Kit in this model.
Transfer of mast cells rendered KitW/Wv mice susceptible to the
K/BxN serum transfer arthritis (Lee et al., 2002). The fact that
we found no evidence for a role of mast cells in the context of
a normal immune system raises the possibility that mast cells
have a propathogenic effect in the context of Kit deficiency.
That factors other than mast cells may be crucial has alsommunity 35, 832–844, November 23, 2011 ª2011 Elsevier Inc. 841
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collagen mAbs, which yielded conflicting results comparing
KitW/Wv and KitW-sh/W-sh mice (Zhou et al., 2007).
Data obtained in the EAE model warrant some additional
considerations. Based on analysis of pure C57BL/6mice without
mast cells (Cre-Master), we consider amajor role for mast cells in
MOG-induced EAE induction or progression unlikely. In the liter-
ature, there are substantial variations in MOG-induced EAE
results in KitW/Wv mice, their MHC-syngeneic wild-type litter
mate controls (WB 3 C57BL/6 Kit+/+), and mast cell-reconsti-
tuted KitW/Wv mice (Bennett et al., 2009; Secor et al., 2000).
Although the reasons for these discrepancies may be manifold,
e.g., mouse colony conditions, microbiota colonization of mice,
or subjective scoring of clinical parameters, our side-by-side
analysis of EAE inCpa3+/+,Cpa3Cre/+, andKitW/Wvmice suggests
that correlations between the numbers and the distribution of
mast cells and EAE pathology do not reflect an active role of
mast cells in this disease.
Collectively, we have generated a mouse line lacking mast
cells by targeted expression of Cre recombinase from the
Cpa3 locus. These mast cell-deficient mice have a normal
immune system but are unable to mount IgE-mediated allergic
responses. However, they are fully susceptible to antibody-
induced autoimmune arthritis and to experimental autoimmune
encephalomyelitis. Although we do not question data obtained
in Kit mutant mice per se, our data provide an example in which
the selective absence of mast cells has different consequences
than the combined deficiency of mast cells and Kit. In our view,
these discrepancies call for a systematic re-evaluation of immu-
nological functions of mast cells beyond allergy.
EXPERIMENTAL PROCEDURES
Gene Targeting and Mice
Generation of Cpa3Cre gene-targeted mice was done as described in the Sup-
plemental Experimental Procedures. All animal procedures were approved by
the local animal committees (Regierungspra¨sidien Tu¨bingen and Karlsruhe or
Kantonales Veterina¨ramt Zu¨rich) and performed in accordance with the institu-
tional guidelines. Cpa3+/+ and Cpa3Cre/+ mice were littermates from at least 12
backcrosses to C57BL/6 or the fourth backcross on BALB/c.
Flow Cytometry and Blood Analyses
Antibodies used are listed in the Supplemental Experimental Procedures. Cells
were stained for flow cytometry as described (Rodewald et al., 1997) and
analyzed on FACS Canto II and LSRFortessa instruments with Diva Software
(BD Biosciences). Hemocytometric parameters of tail vein blood were ob-
tained on an automated hemocytometer according to the manufacturer’s
instructions (ADVIA120; Bayer, Leverkusen, Germany).
Histochemistry
Peritoneal lavage cells were cytospun as described (Feyerabend et al., 2005)
and stained byMay-Gru¨nwald-Giemsa. Tissuemast cells were stained by tolu-
idine blue as described (Feyerabend et al., 2005) or by chloroacetate esterase
(CAE) staining (Supplemental Experimental Procedures).
Skin Inflammation
Phorbol-12-myristate-13-acetate (PMA)-induced skin inflammation was
induced and analyzed as described previously (Waskow et al., 2007).
Anaphylaxis
Passive cutaneous anaphylaxis was done as described (Feyerabend et al.,
2005). For body temperature measurements in passive systemic anaphylaxis,
mice were sensitized intravenously with 20 mg anti-DNP IgE (Sigma), and842 Immunity 35, 832–844, November 23, 2011 ª2011 Elsevier Inc.temperature was monitored rectally after challenge on the next day with
20 mg DNP11-Ova (Biocat). To rescue the defect in anaphylaxis, Cpa3
Cre/+
mice were transplanted with cultured mast cells, derived as described (Feyer-
abend et al., 2005), and challenged by IgE and DNP-Ova. For blood pressure
analyses, mice were sensitized with 50 mg anti-DNP IgE and challenged on the
next day with 500 mg DNP30-40-HSA (Sigma). Blood pressure measurements
were done on anesthetized mice as described in Supplemental Experimental
Procedures.
Serum Immunoglobulins and Anti-NP Immune Response
Steady-state serum immunoglobuline isotypes were quantified with an anti-
kappa light chain capture antibody, mouse immunoglobuline standards, and
horseradish peroxidase-linked isotype-specific detection antibodies (listed
in the Supplemental Experimental Procedures). Tetramethylbenzidine sub-
strate conversion was read at 450 nm on a SpectraMax250 spectrometer
(MWG Biotech). NP-specific antibodies were measured in the serum 2 weeks
after i.p. immunization with 100 mg of 4-hydroxy-3-nitrophenylacetyl-chicken
gamma globulin (NP-CGG, Biosearch Technologies) supplemented with
50 ml Adju-Phos 2% Alum (HCl Biosector). NP-BSA-coated plates, an HRP-
linked IgG1-specific detection antibody, and o-phenylenediamine dihydro-
chloride substrate were used for ELISA. OD values were read at 490 nm.
RNA Expression Analyses
RNA extraction and microarray expression analyses were performed at the
DKFZ genomics and proteomics core facility and were done as described in
Supplemental Experimental Procedures. Samples were hybridized to the
MouseWG-6 v2.0 BeadChip (Illumina). Heat maps of selected genes (Figure 1)
were assembled with the Gene Pattern software package (Broad Institute,
MIT). Hierarchical clustering (Figure 6) was performed with Chipster CSC
v1.4.7. Differentially expressed genes were filtered by standard deviation
(3 SDs = 99.7%), subjected to a several groups test (empirical Bayes method
with Benjamini-Yakutieri test), and hierarchically clustered by Pearson correla-
tion. Preparation of cDNAs and primer sequences for RT-PCRs are described
in the Supplemental Experimental Procedures.
Parasite Infection
Mice were infected subcutaneously with 400 live L3 parasites (Supplemental
Experimental Procedures). At day 10 or 14 after infection, the upper portion
of the jejunum was processed for histology or for RT-PCR and serum was
taken for Mcpt1-specific ELISA (Supplemental Experimental Procedures).
K/BxN Serum Arthritis
12-week-old mice were injected i.p. with 150 ml of pooled arthritogenic K/BxN
serum (Korganow et al., 1999) on experimental days 0 and 2. Mice were
evaluated daily for arthritis severity. Each paw was evaluated and scored
individually with the following scoring system: 0, no evidence of erythema
and swelling; 1, erythema and mild swelling; 2, erythema and pronounced
edematous swelling; 3, ankylosis of the limb. Additionally, ankle thickness of
the hind limbs was measured with a precision caliber (Ka¨fer; dial thickness
gauge). For histopathology, ankles were taken on day 10 after the first
K/BxN serum injection, fixed with paraformaldehyde, decalcified in Kristen-
sen’s solution, embedded in paraffin, and cut in 5 mm sections, and mid-
sagittal ankle sections were stained with hematoxylin and eosin (H&E).
EAE
EAE was induced in mice at 13–15 weeks of age as described in Supplemental
Experimental Procedures. Individual animals were monitored daily for clinical
signs of disease and the disease severity was scored as follows: 0, no signs of
disease; 1, limp tail or hind limb weakness; 2, limp tail and hind limb weakness;
3, partial hind limb paralysis; 4, complete hind limb paralysis; 5, moribund or
dead. Quantification of CNS-infiltrating mononuclear cells, MOG35-55 peptide
restimulation, intracellular cytokine staining, and proliferation are stated in
Supplemental Experimental Procedures.
Statistical Analyses
Statistical analyses in Figures 1, 2, 3, 4, 5, and 7E–7L was performed with
Prism 4 (GraphPad Software) with the unpaired t test except for Figures 1E
and 4D, which were analyzed by one-sample t test. p values are given in the
Immunity
Role of Mast Cells in Autoimmunity Revisitedfigures, and p > 0.05 was considered nonsignificant (n.s.). A two-way ANOVA
for longitudinal data was used to evaluate the differences in response curves of
Cpa3+/+ and Cpa3Cre/+ mice in Figures 6A, 6B, 7, S6A, and S6B. All computa-
tions were performed with the statistical software environment R, version
2.12.2. Values for p > 0.05 were considered nonsignificant.
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